Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled trial including 160 consecutive patients who
have been diagnosed with both rheumatoid arthritis (RA) and low bone mass and have been
treated with alendronate (ALN) for five years or more. Patients will be randomized to
discontinuation or continuation of alendronate. Outcomes are measured using dual energy
absorptiometry (DXA), High Resolution peripheral Quantitative Computer Tomography (HR-pQCT)
and biochemical markers of bone metabolism and inflammation after 6 months, 1 and 2 years.